113 related articles for article (PubMed ID: 33452215)
21. The mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines.
Mattingly RR; Kraniak JM; Dilworth JT; Mathieu P; Bealmear B; Nowak JE; Benjamins JA; Tainsky MA; Reiners JJ
J Pharmacol Exp Ther; 2006 Jan; 316(1):456-65. PubMed ID: 16239399
[TBL] [Abstract][Full Text] [Related]
22. CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon restoration of RB function in malignant peripheral nerve sheath tumors.
Wang J; Calizo A; Zhang L; Pino JC; Lyu Y; Pollard K; Zhang X; Larsson AT; Conniff E; Llosa N; Wood DK; Largaespada DA; Moody SE; Gosline SJ; Hirbe AC; Pratilas CA
bioRxiv; 2023 Feb; ():. PubMed ID: 36778419
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of eight melanocytic and neural crest-associated markers in a well-characterised series of 124 malignant peripheral nerve sheath tumours (MPNST): useful to distinguish MPNST from melanoma?
Gaspard M; Lamant L; Tournier E; Valentin T; Rochaix P; Terrier P; Ranchere-Vince D; Coindre JM; Filleron T; Le Guellec S
Histopathology; 2018 Dec; 73(6):969-982. PubMed ID: 30137667
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine.
Castellsagué J; Gel B; Fernández-Rodríguez J; Llatjós R; Blanco I; Benavente Y; Pérez-Sidelnikova D; García-Del Muro J; Viñals JM; Vidal A; Valdés-Mas R; Terribas E; López-Doriga A; Pujana MA; Capellá G; Puente XS; Serra E; Villanueva A; Lázaro C
EMBO Mol Med; 2015 May; 7(5):608-27. PubMed ID: 25810463
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y
Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032
[TBL] [Abstract][Full Text] [Related]
26. Shipping Out MEK Inhibitor Resistance with SHP2 Inhibitors.
Torres-Ayuso P; Brognard J
Cancer Discov; 2018 Oct; 8(10):1210-1212. PubMed ID: 30279193
[No Abstract] [Full Text] [Related]
27. Beyond "Triton": Malignant Peripheral Nerve Sheath Tumors With Complete Heterologous Rhabdomyoblastic Differentiation Mimicking Spindle Cell Rhabdomyosarcoma.
Hornick JL; Nielsen GP
Am J Surg Pathol; 2019 Oct; 43(10):1323-1330. PubMed ID: 31107719
[TBL] [Abstract][Full Text] [Related]
28. Schwann cell lines derived from malignant peripheral nerve sheath tumors respond abnormally to platelet-derived growth factor-BB.
Dang I; DeVries GH
J Neurosci Res; 2005 Feb; 79(3):318-28. PubMed ID: 15602756
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of MEK inhibition in a recurrent malignant peripheral nerve sheath tumor.
Nagabushan S; Lau LMS; Barahona P; Wong M; Sherstyuk A; Marshall GM; Tyrrell V; Wegner EA; Ekert PG; Cowley MJ; Mayoh C; Trahair TN; Crowe P; Anazodo A; Ziegler DS
NPJ Precis Oncol; 2021 Feb; 5(1):9. PubMed ID: 33580196
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms underlying synergy between DNA topoisomerase I-targeted drugs and mTOR kinase inhibitors in NF1-associated malignant peripheral nerve sheath tumors.
Ki DH; Oppel F; Durbin AD; Look AT
Oncogene; 2019 Sep; 38(39):6585-6598. PubMed ID: 31444410
[TBL] [Abstract][Full Text] [Related]
31. Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft.
Bhola P; Banerjee S; Mukherjee J; Balasubramanium A; Arun V; Karim Z; Burrell K; Croul S; Gutmann DH; Guha A
Int J Cancer; 2010 Jan; 126(2):563-71. PubMed ID: 19634141
[TBL] [Abstract][Full Text] [Related]
32. Upregulated immuno-modulator PD-L1 in malignant peripheral nerve sheath tumors provides a potential biomarker and a therapeutic target.
Farschtschi S; Kluwe L; Park SJ; Oh SJ; Mah N; Mautner VF; Kurtz A
Cancer Immunol Immunother; 2020 Jul; 69(7):1307-1313. PubMed ID: 32193699
[TBL] [Abstract][Full Text] [Related]
33. Epigenomic Reordering Induced by Polycomb Loss Drives Oncogenesis but Leads to Therapeutic Vulnerabilities in Malignant Peripheral Nerve Sheath Tumors.
Wojcik JB; Marchione DM; Sidoli S; Djedid A; Lisby A; Majewski J; Garcia BA
Cancer Res; 2019 Jul; 79(13):3205-3219. PubMed ID: 30898839
[TBL] [Abstract][Full Text] [Related]
34. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in
Sun C; Fang Y; Yin J; Chen J; Ju Z; Zhang D; Chen X; Vellano CP; Jeong KJ; Ng PK; Eterovic AKB; Bhola NH; Lu Y; Westin SN; Grandis JR; Lin SY; Scott KL; Peng G; Brugge J; Mills GB
Sci Transl Med; 2017 May; 9(392):. PubMed ID: 28566428
[TBL] [Abstract][Full Text] [Related]
35. Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.
Linke C; Wösle M; Harder A
BMC Cancer; 2020 Sep; 20(1):896. PubMed ID: 32948135
[TBL] [Abstract][Full Text] [Related]
36. Genomic Profiling in Patients With Malignant Peripheral Nerve Sheath Tumors Reveals Multiple Pathways With Targetable Mutations.
Kaplan HG; Rostad S; Ross JS; Ali SM; Millis SZ
J Natl Compr Canc Netw; 2018 Aug; 16(8):967-974. PubMed ID: 30099373
[No Abstract] [Full Text] [Related]
37. Non-cytotoxic systemic treatment in malignant peripheral nerve sheath tumors (MPNST): A systematic review from bench to bedside.
Martin E; Lamba N; Flucke UE; Verhoef C; Coert JH; Versleijen-Jonkers YMH; Desar IME
Crit Rev Oncol Hematol; 2019 Jun; 138():223-232. PubMed ID: 31092379
[TBL] [Abstract][Full Text] [Related]
38. Superficial malignant peripheral nerve sheath tumor from recurrent neurofibroma in the abdominal wall of a patient without neurofibromatosis type 1.
Jung CY; Bae JM; Choi JH; Jung KH
Yeungnam Univ J Med; 2019 Jan; 36(1):63-66. PubMed ID: 31620615
[TBL] [Abstract][Full Text] [Related]
39. Galectin-1 inhibition induces cell apoptosis through dual suppression of CXCR4 and Ras pathways in human malignant peripheral nerve sheath tumors.
Shih TC; Fan Y; Kiss S; Li X; Deng XN; Liu R; Chen XJ; Carney R; Chen A; Ghosh PM; Lam KS
Neuro Oncol; 2019 Nov; 21(11):1389-1400. PubMed ID: 31127849
[TBL] [Abstract][Full Text] [Related]
40. Incidence of second malignancies in individuals diagnosed with malignant peripheral nerve sheath tumors.
Williams LA; Moertel CL; Richardson M; Marcotte EL
J Neurooncol; 2020 May; 147(3):701-709. PubMed ID: 32239432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
